Cargando…
Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
Immunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312945/ https://www.ncbi.nlm.nih.gov/pubmed/35885047 http://dx.doi.org/10.3390/biomedicines10071738 |
_version_ | 1784753957608882176 |
---|---|
author | Elmadany, Nirmeen Alhalabi, Obada T. Platten, Michael Bunse, Lukas |
author_facet | Elmadany, Nirmeen Alhalabi, Obada T. Platten, Michael Bunse, Lukas |
author_sort | Elmadany, Nirmeen |
collection | PubMed |
description | Immunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric antigen receptors (CAR) T cell therapy, which demonstrated promising clinical responses in other solid tumors. Current pre-clinical and interventional clinical studies suggest improved efficacy when CAR-T cells are delivered locoregionally, rather than intravenously. In this review, we summarize possible CAR-T cell administration routes including locoregional therapy, systemic administration with and without focused ultrasound, direct intra-arterial drug delivery and nanoparticle-enhanced delivery in glioma. Moreover, we discuss published as well as ongoing and planned clinical trials involving CAR-T cell therapy in malignant glioma. With increasing neoadjuvant and/or adjuvant combinatorial immunotherapeutic concepts and modalities with specific modes of action for malignant glioma, selection of administration routes becomes increasingly important. |
format | Online Article Text |
id | pubmed-9312945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93129452022-07-26 Site-Specific Considerations on Engineered T Cells for Malignant Gliomas Elmadany, Nirmeen Alhalabi, Obada T. Platten, Michael Bunse, Lukas Biomedicines Review Immunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric antigen receptors (CAR) T cell therapy, which demonstrated promising clinical responses in other solid tumors. Current pre-clinical and interventional clinical studies suggest improved efficacy when CAR-T cells are delivered locoregionally, rather than intravenously. In this review, we summarize possible CAR-T cell administration routes including locoregional therapy, systemic administration with and without focused ultrasound, direct intra-arterial drug delivery and nanoparticle-enhanced delivery in glioma. Moreover, we discuss published as well as ongoing and planned clinical trials involving CAR-T cell therapy in malignant glioma. With increasing neoadjuvant and/or adjuvant combinatorial immunotherapeutic concepts and modalities with specific modes of action for malignant glioma, selection of administration routes becomes increasingly important. MDPI 2022-07-19 /pmc/articles/PMC9312945/ /pubmed/35885047 http://dx.doi.org/10.3390/biomedicines10071738 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Elmadany, Nirmeen Alhalabi, Obada T. Platten, Michael Bunse, Lukas Site-Specific Considerations on Engineered T Cells for Malignant Gliomas |
title | Site-Specific Considerations on Engineered T Cells for Malignant Gliomas |
title_full | Site-Specific Considerations on Engineered T Cells for Malignant Gliomas |
title_fullStr | Site-Specific Considerations on Engineered T Cells for Malignant Gliomas |
title_full_unstemmed | Site-Specific Considerations on Engineered T Cells for Malignant Gliomas |
title_short | Site-Specific Considerations on Engineered T Cells for Malignant Gliomas |
title_sort | site-specific considerations on engineered t cells for malignant gliomas |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312945/ https://www.ncbi.nlm.nih.gov/pubmed/35885047 http://dx.doi.org/10.3390/biomedicines10071738 |
work_keys_str_mv | AT elmadanynirmeen sitespecificconsiderationsonengineeredtcellsformalignantgliomas AT alhalabiobadat sitespecificconsiderationsonengineeredtcellsformalignantgliomas AT plattenmichael sitespecificconsiderationsonengineeredtcellsformalignantgliomas AT bunselukas sitespecificconsiderationsonengineeredtcellsformalignantgliomas |